Evaluation of Apatinib-Related Hypertension and Identification of Clinical Risk Factors
Table 2
Patient demographic and baseline characteristics.
Patient characteristics
Total cohort (N = 55)
Apatinib-related HTN (N = 25)
No apatinib-related HTN (N = 30)
value
Male gender
40 (72.73)
19 (76.00)
21 (70.00)
0.619
Age (years)
58.40 ± 10.05
59.84 ± 8.76
57.20 ± 11.02
0.332
BMI (kg/m2)
22.69 ± 3.45
23.72 ± 3.36
21.82 ± 3.33
0.042
TNM classification
0.204
III
6 (10.91)
1 (4.00)
5 (16.67)
IV
49 (89.09)
24 (96.00)
25 (83.33)
Prior operation
22 (40.00)
9 (36.00)
13 (43.33)
0.580
Prior radiotherapy
3 (5.45)
0
3 (10.00)
1.000
Smoker
20 (36.36)
5 (20.00)
15 (50.00)
0.959
Diabetes mellitus
13 (23.64)
7 (28.00)
6 (20.00)
0.487
Preexisting HTN
22 (40.00)
15 (60.00)
7 (23.33)
0.006
ECOG PS
0.440
0
14 (25.45)
7 (28.00)
7 (23.33)
1
33 (60.00)
13 (52.00)
20 (66.67)
≥2
8 (14.55)
5 (20.00)
3 (10.00)
Number of metastatic sites
1.000
0–2
51 (92.73)
23 (92.00)
28 (93.33)
≥3
4 (7.27)
2 (8.00)
2 (6.67)
Baseline SBP (mm·Hg)
120.49 ± 9.51
121.64 ± 10.77
119.53 ± 8.38
0.413
Baseline DBP (mm·Hg)
76.87 ± 6.70
77.16 ± 7.59
76.63 ± 5.97
0.772
Apatinib therapy
0.210
Initial dose 125–250 mg QD
34 (61.82)
13 (52.00)
21 (70.00)
Initial dose 425–500 mg QD
20 (36.36)
11 (44.00)
9 (30.00)
Initial dose 750–850 mg QD
1 (1.82)
1 (4.00)
0
Data are presented as a number with percent (%) and mean ± standard deviation. Demographic parameters are significantly different between study groups (). HTN: hypertension; QD: once daily; ECOG: Eastern Cooperative Oncology Group performance status; BP: blood pressure; BMI: body mass index.
